[{"orgOrder":0,"company":"Evergreen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"EG-007","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Evergreen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evergreen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evergreen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Evergreen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"EG-007","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Evergreen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evergreen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evergreen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Evergreen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"EG-009","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Evergreen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evergreen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evergreen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Evergreen Therapeutics","sponsor":"Icon Plc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"EG-009A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Evergreen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evergreen Therapeutics \/ Evergreen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Evergreen Therapeutics \/ Evergreen Therapeutics"},{"orgOrder":0,"company":"Evergreen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"EG-301","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Evergreen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Evergreen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evergreen Therapeutics \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Evergreen Therapeutics

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check all FDF Dossiers for
this supplier

Contact Us
PharmaScopic.com

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Evergreen Therapeutics

Country

The MedTech Conference

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : EG-301

Therapeutic Area : Ophthalmology

Study Phase : Phase II

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Study to Evaluate Safety and Efficacy of EG-301 in Patients with Nonfocal Geographic Atrophy Secondary to DAMD

Details : EG-301 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Macular Degeneration.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Inapplicable

December 27, 2021

Lead Product(s) : EG-301

Therapeutic Area : Ophthalmology

Highest Development Status : Phase II

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

Evergreen Therapeutics

Country

The MedTech Conference

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : EG-007

Therapeutic Area : Oncology

Study Phase : Phase II

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

Details : EG-007 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Endometrial Neoplasms.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Inapplicable

November 03, 2021

Lead Product(s) : EG-007

Therapeutic Area : Oncology

Highest Development Status : Phase II

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

03

Evergreen Therapeutics

Country

The MedTech Conference

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : EG-007

Therapeutic Area : Oncology

Study Phase : Phase III

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Canc...

Details : EG-007 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Endometrial Neoplasms.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Inapplicable

October 14, 2021

Lead Product(s) : EG-007

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

04

Evergreen Therapeutics

Country

The MedTech Conference

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : EG-009A

Therapeutic Area : Infections and Infectious Diseases

Study Phase : Phase I

Recipient : Icon Plc

Deal Size : Undisclosed

Deal Type : Agreement

Evergreen Therapeutics Announces Agreement with ICON to Conduct Phase II Clinical Trial for COVID-19 Drug Cand...

Details : The purpose of the study is to evaluate the efficacy of Evergreen’s EG-009A drug candidate for the treatment of moderate to severe COVID-19 cases.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Undisclosed

June 18, 2021

Lead Product(s) : EG-009A

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Recipient : Icon Plc

Deal Size : Undisclosed

Deal Type : Agreement

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

05

Evergreen Therapeutics

Country

The MedTech Conference

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : EG-009

Therapeutic Area : Infections and Infectious Diseases

Study Phase : Phase II

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia

Details : EG-009 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Inapplicable

September 23, 2020

Lead Product(s) : EG-009

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase II

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow